Your session is about to expire
← Back to Search
Donor Matching Strategies for Blood Cancer Transplants (BMT CTN 1702 Trial)
N/A
Waitlist Available
Research Sponsored by Center for International Blood and Marrow Transplant Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified
Signed informed consent, and assent if applicable. Consent may be signed prior to completion of family typing but patients will only be considered evaluable upon confirmation that there is no suitable HLA-identical or 1 allele or antigen mismatched related donor available
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
BMT CTN 1702 Trial Summary
This trial will compare two ways of finding a donor for a person with blood cancer who needs a transplant.
Who is the study for?
This trial is for patients with conditions like various leukemias, lymphomas, sickle cell disease, and aplastic anemia who need a stem cell transplant but don't have a closely matched family donor. They should be fit for transplantation based on their medical history and tests. Patients already having had an allogeneic transplant can't join.Check my eligibility
What is being tested?
The study aims to see if searching for a fully matched unrelated donor before considering alternative donors leads to better survival within two years after joining the study compared to going straight to an alternative donor transplant.See study design
What are the potential side effects?
While specific side effects are not listed here, allogeneic transplants typically carry risks such as graft-versus-host disease (where the new cells attack your body), infections due to weakened immune system, organ damage, and reactions from the conditioning regimen.
BMT CTN 1702 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I plan to have a stem cell transplant from a donor within 6 months if we find a match.
Select...
I have signed the consent form and understand the study.
BMT CTN 1702 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Survival for MUD Very Likely and MUD Very Unlikely Arms
Secondary outcome measures
Barriers to Transplant
Cumulative Incidence of Transplant by Donor Search Prognosis Score
Other outcome measures
AML or ALL in first complete remission or early stage MDS Substudy - CRFS
Muscular Dystrophy
AML or ALL in first complete remission or early stage MDS Substudy - QoL
+15 moreBMT CTN 1702 Trial Design
3Treatment groups
Experimental Treatment
Group I: Donor Search Prognosis: MUD Very UnlikelyExperimental Treatment1 Intervention
Patients who are Very Unlikely to find a MUD, defined as having a <10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
Group II: Donor Search Prognosis: MUD Very LikelyExperimental Treatment1 Intervention
Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a >90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
Group III: Donor Search Prognosis: MUD Less LikelyExperimental Treatment1 Intervention
Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
Find a Location
Who is running the clinical trial?
National Marrow Donor ProgramOTHER
60 Previous Clinical Trials
200,807 Total Patients Enrolled
Medical College of WisconsinOTHER
609 Previous Clinical Trials
1,160,848 Total Patients Enrolled
Blood and Marrow Transplant Clinical Trials NetworkNETWORK
49 Previous Clinical Trials
12,229 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a family member who could be a donor but is deemed unsuitable by the medical center.I am deemed fit for a transplant from another person based on my health records and tests.I have not had a transplant from another person.My doctor will decide if I'm fit for a transplant based on my organ function tests, if available.I plan to have a stem cell transplant from a donor within 6 months if we find a match.I have signed the consent form and understand the study.I don't have a closely matched family donor for a transplant.My treatment plan includes any type of preparation and graft-versus-host disease prevention.I have been diagnosed with AML, ALL, MDS, NHL, HL, AA, or SCD.
Research Study Groups:
This trial has the following groups:- Group 1: Donor Search Prognosis: MUD Less Likely
- Group 2: Donor Search Prognosis: MUD Very Likely
- Group 3: Donor Search Prognosis: MUD Very Unlikely
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is the recruitment for this research endeavor ongoing?
"Data hosted on clinicaltrials.gov states that this medical trial is currently not accepting patients as of September 15th 2022. The study was first posted in June 14th 2019 but has since been discontinued, however there are numerous other studies actively recruiting at this time with a total of 3306 open trials available."
Answered by AI
How many healthcare institutions are actively participating in this investigation?
"Enrolment into this clinical trial has been made available at 51 different sites, such as Children's Healthcare of Atlanta in Atlanta and the University of Mississippi in Jackson. Furthermore, there are also 48 other locations that offer enrolment for this medical study."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger